Empryrean Bioscience obtains dismissal of securities litigation
Clients Empyrean Bioscience
Jones Day represented Empyrean Bioscience, Inc., a marketer of personal care disease-prevention products, and certain officers and directors in an action alleging securities disclosure violations in connection with the status of an application for FDA product approval. The ruling granted dismissal of plaintiffs' Securities Act claim with prejudice and dismissal of the Securities Exchange Act claim with leave to amend.
In re Empyrean Bioscience, Inc. Securities Litigation, No. 1:02-CV-1439 (N.D. Ohio)